Others

Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials

CompanyDeals

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

CompanyDeals

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

CompanyDrug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

CompanyDrug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

CompanyDrug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

CompanyDeals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Company

AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification

CompanyDrug

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
CompanyDeals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

CompanyDrug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

CompanyDrug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly